HomepageHPX • FRA
add
Hisamitsu Pharmaceutical Co Inc
Vorige slotkoers
€ 26,80
Dag-range
€ 25,80 - € 25,80
Jaar-range
€ 21,00 - € 28,80
Beurswaarde
369,10Â mld. JPY
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | feb 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 44,75Â mld. | 15,11% |
Bedrijfskosten | 19,13Â mld. | -1,75% |
Netto inkomsten | 8,10Â mld. | 335,61% |
Netto winstmarge | 18,09 | 278,45% |
Winst per aandeel | — | — |
EBITDA | 7,26Â mld. | 231,30% |
Effectief belastingtarief | 11,16% | — |
Balans
Totale activa
Totale passiva
(JPY) | feb 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 129,12Â mld. | 3,03% |
Totale activa | 343,07Â mld. | 4,35% |
Totale passiva | 63,66Â mld. | 3,18% |
Totaal aandelenvermogen | 279,40 mld. | — |
Uitstaande aandelen | 72,96 mln. | — |
Koers-boekwaardeverhouding | 0,01 | — |
Rendement op activa | 4,19% | — |
Rendement op kapitaal | 5,17% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | feb 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 8,10Â mld. | 335,61% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
Opgericht
1847
Hoofdvestiging
Website
Werknemers
2.759